Top

Infectious Diseases and Therapy

Published in:

Open Access 10-10-2023 | Tuberculosis | Original Research

The Causal Impact of the Gut Microbiota on Respiratory Tuberculosis Susceptibility

Authors: Jiayu Wen, Jian-Qing He

Published in: Infectious Diseases and Therapy | Issue 11/2023

Abstract

Introduction

Recent cross-sectional research has demonstrated a substantial link between tuberculosis (TB) and gut microbiota. Nevertheless, the causal impact of the gut microbiota on TB susceptibility in humans remains unknown.

Methods

The Mendelian randomization (MR) method was utilized for investigating the causality between them. The main method used for MR analysis was the inverse variance weighted (IVW) test, with the MR-Egger, weighted median, weighted mode, and simple median methods serving as supplements. And several sensitivity tests were carried out to validate the MR findings.

Results

The IVW outcomes suggested that three bacterial traits exhibited associations with susceptibility to respiratory TB after Bonferroni correction, namely Lachnospiraceae UCG010 (odds ratio [OR] 1.73, 95% confidence interval [CI] 1.17–2.55, P = 0.005), Eubacterium (brachy group) (OR 1.33, 95% CI 1.07–1.65, P = 0.009), and Ruminococcaceae UCG005 (OR 0.71, 95% CI 0.52–0.98, P = 0.034). Sensitivity analyses demonstrated that horizontal pleiotropy and heterogeneity were absent, thereby guaranteeing the reliability of the results.

Conclusion

This research sheds light on the causal impact of gut microbiota on respiratory tuberculosis susceptibility, improving our knowledge of therapeutic strategies for managing TB.

Available only for authorised users

World Health Organization. Geneva: Global Tuberculosis Report; 2021. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. Accessed 2023 Jun 23.

Lyon SM, Rossman MD. Pulmonary tuberculosis. Microbiol Spectrum. 2017. https://doi.org/10.1128/microbiolspec.tnmi7-0032-2016.CrossRef

Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15(1):55–63. https://doi.org/10.1038/nrmicro.2016.142.CrossRefPubMed

Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The role of lung and gut microbiota in the pathology of asthma. Immunity. 2020;52(2):241–55. https://doi.org/10.1016/j.immuni.2020.01.007.CrossRefPubMedPubMedCentral

Dayama G, Priya S, Niccum DE, Khoruts A, Blekhman R. Interactions between the gut microbiome and host gene regulation in cystic fibrosis. Genome Med. 2020;12(1):12. https://doi.org/10.1186/s13073-020-0710-2.CrossRefPubMedPubMedCentral

Zhang F, Lau RI, Liu Q, Su Q, Chan FKL, Ng SC. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2023;20(5):323–37. https://doi.org/10.1038/s41575-022-00698-4.CrossRefPubMed

Yang F, Yang Y, Chen L, et al. The gut microbiota mediates protective immunity against tuberculosis via modulation of lncRNA. Gut Microbes. 2022;14(1):2029997. https://doi.org/10.1080/19490976.2022.2029997.CrossRefPubMedPubMedCentral

Khan N, Vidyarthi A, Nadeem S, Negi S, Nair G, Agrewala JN. Alteration in the gut microbiota provokes susceptibility to tuberculosis. Front Immunol. 2016;7:529. https://doi.org/10.3389/fimmu.2016.00529.CrossRefPubMedPubMedCentral

Wang H, Yao J, Chen Y, et al. Gut dysbacteriosis attenuates resistance to Mycobacterium bovis infection by decreasing cyclooxygenase 2 to inhibit endoplasmic reticulum stress. Emerg Microbes Infect. 2022;11(1):1806–18. https://doi.org/10.1080/22221751.2022.2096486.CrossRefPubMedPubMedCentral

10.

Dumas A, Corral D, Colom A, et al. The host microbiota contributes to early protection against lung colonization by Mycobacterium tuberculosis. Front Immunol. 2018;9:2656. https://doi.org/10.3389/fimmu.2018.02656.CrossRefPubMedPubMedCentral

11.

Eribo OA, Naidoo CC, Theron G, Walzl G, du Plessis N, Chegou NN. An archetypical model for engrafting Bacteroides fragilis into conventional mice following reproducible antibiotic conditioning of the gut microbiota. Microorganisms. 2023. https://doi.org/10.3390/microorganisms11020451.CrossRefPubMedPubMedCentral

12.

Chen L, Zhang G, Li G, et al. Ifnar gene variants influence gut microbial production of palmitoleic acid and host immune responses to tuberculosis. Nat Metab. 2022;4(3):359–73. https://doi.org/10.1038/s42255-022-00547-3.CrossRefPubMed

13.

Ding X, Zhou J, Chai Y, et al. A metagenomic study of the gut microbiome in PTB’S disease. Microbes Infect. 2022;24(2): 104893. https://doi.org/10.1016/j.micinf.2021.104893.CrossRefPubMed

14.

Hu Y, Feng Y, Wu J, et al. The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients. Front Cell Infect Microbiol. 2019;9:90. https://doi.org/10.3389/fcimb.2019.00090.CrossRefPubMedPubMedCentral

15.

Luo M, Liu Y, Wu P, et al. Alternation of gut microbiota in patients with pulmonary tuberculosis. Front Physiol. 2017;8:822. https://doi.org/10.3389/fphys.2017.00822.CrossRefPubMedPubMedCentral

16.

Hu Y, Yang Q, Liu B, et al. Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs. J Infect. 2019;78(4):317–22. https://doi.org/10.1016/j.jinf.2018.08.006.CrossRefPubMed

17.

Shi W, Hu Y, Ning Z, et al. Alterations of gut microbiota in patients with active pulmonary tuberculosis in China: a pilot study. Int J Infect Dis. 2021;111:313–21. https://doi.org/10.1016/j.ijid.2021.08.064.CrossRefPubMed

18.

Khaliq A, Ravindran R, Afzal S, et al. Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting. PLoS ONE. 2021;16(1):e0245534. https://doi.org/10.1371/journal.pone.0245534.CrossRefPubMedPubMedCentral

19.

Naidoo CC, Nyawo GR, Sulaiman I, et al. Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis. EBioMedicine. 2021;67:103374. https://doi.org/10.1016/j.ebiom.2021.103374.CrossRefPubMedPubMedCentral

20.

Wipperman MF, Fitzgerald DW, Juste MAJ, et al. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci Rep. 2017;7(1):10767. https://doi.org/10.1038/s41598-017-10346-6.CrossRefPubMedPubMedCentral

21.

Zuccolo L, Holmes MV. Commentary: Mendelian randomization-inspired causal inference in the absence of genetic data. Int J Epidemiol. 2017;46(3):962–5. https://doi.org/10.1093/ije/dyw327.CrossRefPubMed

22.

Davies NM, Holmes MV, Davey SG. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362: k601. https://doi.org/10.1136/bmj.k601.CrossRefPubMedPubMedCentral

23.

Song J, Wu Y, Yin X, Ma H, Zhang J. The causal links between gut microbiota and COVID-19: a Mendelian randomization study. J Med Virol. 2023;95(5):e28784. https://doi.org/10.1002/jmv.28784.CrossRefPubMed

24.

Long Y, Tang L, Zhou Y, Zhao S, Zhu H. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study. BMC Med. 2023;21(1):66. https://doi.org/10.1186/s12916-023-02761-6.CrossRefPubMedPubMedCentral

25.

Amin N, Liu J, Bonnechere B, et al. Interplay of metabolome and gut microbiome in individuals with major depressive disorder vs control individuals. JAMA Psychiat. 2023;80(6):597–609. https://doi.org/10.1001/jamapsychiatry.2023.0685.CrossRef

26.

Kurilshikov A, Medina-Gomez C, Bacigalupe R, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021;53(2):156–65. https://doi.org/10.1038/s41588-020-00763-1.CrossRefPubMedPubMedCentral

27.

Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178(7):1177–84. https://doi.org/10.1093/aje/kwt084.CrossRefPubMedPubMedCentral

28.

Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40(7):597–608. https://doi.org/10.1002/gepi.21998.CrossRefPubMedPubMedCentral

29.

Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291–5. https://doi.org/10.1038/ng.3211.CrossRefPubMedPubMedCentral

30.

Boef AG, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015;44(2):496–511. https://doi.org/10.1093/ije/dyv071.CrossRefPubMed

31.

Restrepo BI. Diabetes and tuberculosis. Microbiol Spectr. 2016. https://doi.org/10.1128/microbiolspec.TNMI7-0023-2016.CrossRefPubMed

32.

Simou E, Britton J, Leonardi-Bee J. Alcohol consumption and risk of tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2018;22(11):1277–85. https://doi.org/10.5588/ijtld.18.0092.CrossRefPubMed

33.

Amere GA, Nayak P, Salindri AD, Narayan KMV, Magee MJ. Contribution of smoking to tuberculosis incidence and mortality in high-tuberculosis-burden countries. Am J Epidemiol. 2018;187(9):1846–55. https://doi.org/10.1093/aje/kwy081.CrossRefPubMedPubMedCentral

34.

Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39(1):149–55. https://doi.org/10.1093/ije/dyp308.CrossRefPubMed

35.

Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–602. https://doi.org/10.1016/s0140-6736(16)31678-6.

36.

Mukamal KJ, Stampfer MJ, Rimm EB. Genetic instrumental variable analysis: time to call mendelian randomization what it is. The example of alcohol and cardiovascular disease. Eur J Epidemiol. 2020;35(2):93–7. https://doi.org/10.1007/s10654-019-00578-3.CrossRefPubMed

37.

Dan YL, Wang P, Cheng Z, et al. Circulating adiponectin levels and systemic lupus erythematosus: a two-sample Mendelian randomization study. Rheumatology (Oxf). 2021;60(2):940–6. https://doi.org/10.1093/rheumatology/keaa506.CrossRef

38.

Boehm FJ, Zhou X. Statistical methods for Mendelian randomization in genome-wide association studies: a review. Comput Struct Biotechnol J. 2022;20:2338–51. https://doi.org/10.1016/j.csbj.2022.05.015.CrossRefPubMedPubMedCentral

39.

Walker VM, Davies NM, Hemani G, et al. Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. Wellcome Open Res. 2019;4:113. https://doi.org/10.12688/wellcomeopenres.15334.2.CrossRefPubMedPubMedCentral

40.

Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14. https://doi.org/10.1002/gepi.21965.CrossRefPubMedPubMedCentral

41.

Li W, Zhu Y, Liao Q, Wang Z, Wan C. Characterization of gut microbiota in children with pulmonary tuberculosis. BMC Pediatr. 2019;19(1):445. https://doi.org/10.1186/s12887-019-1782-2.CrossRefPubMedPubMedCentral

42.

Chen Z, Radjabzadeh D, Chen L, et al. Association of insulin resistance and type 2 diabetes with gut microbial diversity: a microbiome-wide analysis from population studies. JAMA Netw Open. 2021;4(7):e2118811. https://doi.org/10.1001/jamanetworkopen.2021.18811.CrossRefPubMedPubMedCentral

43.

Esquivel-Hernández DA, Martínez-López YE, Sánchez-Castañeda JP, et al. A network perspective on the ecology of gut microbiota and progression of type 2 diabetes: linkages to keystone taxa in a Mexican cohort. Front Endocrinol (Lausanne). 2023;14:1128767. https://doi.org/10.3389/fendo.2023.1128767.CrossRefPubMed

44.

Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol. 2014;2(9):730–9. https://doi.org/10.1016/s2213-8587(14)70109-3.CrossRefPubMed

45.

Sommer AJ, Peters A, Rommel M, et al. A randomization-based causal inference framework for uncovering environmental exposure effects on human gut microbiota. PLoS Comput Biol. 2022;18(5): e1010044. https://doi.org/10.1371/journal.pcbi.1010044.CrossRefPubMedPubMedCentral

46.

Brandenburg J, Marwitz S, Tazoll SC, et al. WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis. J Clin Invest. 2021. https://doi.org/10.1172/jci141833.CrossRefPubMedPubMedCentral

47.

Chidambaram V, Zhou L, Ruelas Castillo J, et al. Higher serum cholesterol levels are associated with reduced systemic inflammation and mortality during tuberculosis treatment independent of body mass index. Front Cardiovasc Med. 2021;8:696517. https://doi.org/10.3389/fcvm.2021.696517.CrossRefPubMedPubMedCentral

48.

Namasivayam S, Kauffman KD, McCulloch JA, et al. Correlation between disease severity and the intestinal microbiome in Mycobacterium tuberculosis-infected Rhesus macaques. mBio. 2019. https://doi.org/10.1128/mBio.01018-19.CrossRefPubMedPubMedCentral

49.

Huang Y, Tang JH, Cai Z, et al. Alterations in the nasopharyngeal microbiota associated with active and latent tuberculosis. Tuberculosis (Edinb). 2022;136:102231. https://doi.org/10.1016/j.tube.2022.102231.CrossRefPubMed

50.

Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. https://doi.org/10.1038/nature11450.CrossRefPubMed

51.

Kameyama K, Itoh K. Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ. 2014;29(4):427–30. https://doi.org/10.1264/jsme2.ME14054.CrossRefPubMedPubMedCentral

52.

Maji A, Misra R, Dhakan DB, et al. Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers. Environ Microbiol. 2018;20(1):402–19. https://doi.org/10.1111/1462-2920.14015.CrossRefPubMed

53.

Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000;47(3):397–403. https://doi.org/10.1136/gut.47.3.397.

54.

Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002;20:581–620. https://doi.org/10.1146/annurev.immunol.20.081501.125851.CrossRefPubMed

55.

McCaffrey EF, Donato M, Keren L, et al. The immunoregulatory landscape of human tuberculosis granulomas. Nat Immunol. 2022;23(2):318–29. https://doi.org/10.1038/s41590-021-01121-x.CrossRefPubMedPubMedCentral

56.

Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet. 2012;90(1):7–24. https://doi.org/10.1016/j.ajhg.2011.11.029.CrossRefPubMedPubMedCentral

Title: The Causal Impact of the Gut Microbiota on Respiratory Tuberculosis Susceptibility
Authors: Jiayu Wen
Jian-Qing He
Publication date: 10-10-2023
Publisher: Springer Healthcare
Keywords: Tuberculosis
Tuberculosis
Respiratory Microbiota
Published in: Infectious Diseases and Therapy / Issue 11/2023
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-023-00880-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2023

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study

The Present and Future Aspects of Life-Long Pertussis Prevention: Narrative Review with Regional Perspectives for Türkiye

Characterization of a Tigecycline-, Linezolid- and Vancomycin-Resistant Clinical Enteroccoccus faecium Isolate, Carrying vanA and vanB Genes

Correction to: Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies

Disease Burden of Meningitis Caused by Streptococcus pneumoniae Among Under-Fives in China: A Systematic Review and Meta-analysis

Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials